Latest Pharma Insights
US Content Creators Certification Program Should Strengthen Creator-Brand Partnerships
The BBB National Programs’ Institute for Responsible Influence will launch its certification program this spring, provide a searchable database of certified creators and promote accountability in creator-brand partnerships.
HBW Insight - January 24, 2026
The BBB National Programs’ Institute for Responsible Influence will launch its certification program this spring, provide a searchable database of certified creators and promote accountability in creator-brand partnerships.
HBW Insight - January 24, 2026
Intuitive Eyes Opportunities In Cardiac Care, Outpatient Centers
The FDA has cleared Intuitive Surgical’s da Vinci 5 for some cardiac procedures, opening new opportunities for the firm. The company is also looking to expand its presence in ambulatory surgical centers, execs said during a Jan. 22 earnings call.
Medtech Insight - January 24, 2026
The FDA has cleared Intuitive Surgical’s da Vinci 5 for some cardiac procedures, opening new opportunities for the firm. The company is also looking to expand its presence in ambulatory surgical centers, execs said during a Jan. 22 earnings call.
Medtech Insight - January 24, 2026
Scrip JPM Podcast: Dealmaking, Regulatory And Commercial Expectations For 2026
Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.
Scrip - January 23, 2026
Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.
Scrip - January 23, 2026
Bausch Health Needs Plan B After RED-C Trials Fail
The company said amorphous rifaximin solid soluble dispersion did not meet the primary endpoint in two Phase III RED-C trials in the prevention of hepatic encephalopathy in patients with cirrhosis.
Scrip - January 23, 2026
The company said amorphous rifaximin solid soluble dispersion did not meet the primary endpoint in two Phase III RED-C trials in the prevention of hepatic encephalopathy in patients with cirrhosis.
Scrip - January 23, 2026
Finance Watch: Nearly $3.5bn In Biopharma Venture Capital Raised So Far In 2026
Private Company Edition: Twenty eight biopharma firms announced $2.11bn in new VC funding between Jan. 8 and 22 on top of $1.36bn in pre-J.P. Morgan disclosures on Jan. 7 and 8. Corxel led the recent financings with a $287m series D1 round to advance its oral GLP-1 agonist.
Scrip - January 23, 2026
Private Company Edition: Twenty eight biopharma firms announced $2.11bn in new VC funding between Jan. 8 and 22 on top of $1.36bn in pre-J.P. Morgan disclosures on Jan. 7 and 8. Corxel led the recent financings with a $287m series D1 round to advance its oral GLP-1 agonist.
Scrip - January 23, 2026
Sanofi Upbeat About Amlitelimab Despite More Mixed Results
The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.
Scrip - January 23, 2026
The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.
Scrip - January 23, 2026
Pipeline Watch: One Approval And Five Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - January 23, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - January 23, 2026
BMS Continues Its Oncology Dealmaking Spree With Janux
Deal Snapshot: BMS is casting a broad net in oncology as it looks to replace its aging blockbuster Opdivo with a variety of novel cancer therapies.
Scrip - January 23, 2026
Deal Snapshot: BMS is casting a broad net in oncology as it looks to replace its aging blockbuster Opdivo with a variety of novel cancer therapies.
Scrip - January 23, 2026
Restari Picks Up AriBio’s PDE-5 Inhibitor In $230m Deal
AriBio reaches an exclusive global out-licensing deal with Restari for its next generation PDE-5 inhibitor.
Scrip - January 23, 2026
AriBio reaches an exclusive global out-licensing deal with Restari for its next generation PDE-5 inhibitor.
Scrip - January 23, 2026
SK bioscience, MSD, Hilleman Join Hands On Zaire Ebolavirus Vaccine
A CEPI-supported partnership between MSD Hilleman and SK bioscience aims to improve Ebola vaccine manufacturing and supply.
Scrip - January 23, 2026
A CEPI-supported partnership between MSD Hilleman and SK bioscience aims to improve Ebola vaccine manufacturing and supply.
Scrip - January 23, 2026
Intuitive Eyes Opportunities In Cardiac Care, Outpatient Centers
The FDA has cleared Intuitive Surgical’s da Vinci 5 for some cardiac procedures, opening new opportunities for the firm. The company is also looking to expand its presence in ambulatory surgical centers, execs said during a Jan. 22 earnings call.
Medtech Insight - January 24, 2026
The FDA has cleared Intuitive Surgical’s da Vinci 5 for some cardiac procedures, opening new opportunities for the firm. The company is also looking to expand its presence in ambulatory surgical centers, execs said during a Jan. 22 earnings call.
Medtech Insight - January 24, 2026
US Content Creators Certification Program Should Strengthen Creator-Brand Partnerships
The BBB National Programs’ Institute for Responsible Influence will launch its certification program this spring, provide a searchable database of certified creators and promote accountability in creator-brand partnerships.
HBW Insight - January 24, 2026
The BBB National Programs’ Institute for Responsible Influence will launch its certification program this spring, provide a searchable database of certified creators and promote accountability in creator-brand partnerships.
HBW Insight - January 24, 2026
BMS To Continue Legal Action As Zydus Launches First Cut-Price Nivolumab Biosimilar In India
BMS will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company.
Generics Bulletin - January 23, 2026
BMS will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company.
Generics Bulletin - January 23, 2026
Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - January 23, 2026
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - January 23, 2026
Towa, Otsuka Launch Cross-Sector Alliance For Long-Listed And Off-Patent Drugs
The leading Japanese generics player and local originator will collaborate on technology transfer, contract manufacturing and product succession as part of a cross-sector effort to strengthen supply chains for long-listed and off-patent medicines.
Generics Bulletin - January 23, 2026
The leading Japanese generics player and local originator will collaborate on technology transfer, contract manufacturing and product succession as part of a cross-sector effort to strengthen supply chains for long-listed and off-patent medicines.
Generics Bulletin - January 23, 2026
Podcast: Herantis’s ‘Elegant’ Approach In Parkinson’s
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
In Vivo - January 22, 2026
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
In Vivo - January 22, 2026
Priya Singhal’s Blueprint For Biogen’s Next Act
Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.
In Vivo - January 22, 2026
Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.
In Vivo - January 22, 2026
Medable Bets Agentic AI Can Crack Clinical Development’s Manual Labor Problem
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.
In Vivo - January 22, 2026
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.
In Vivo - January 22, 2026
Execs On The Move: December 2025
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - January 22, 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - January 22, 2026